UniCredit-Backed Alpha Bank Plans SRT on €1.2 Billion of Loans
The size of the reference portfolio is about €1.2 billion ($1.4 billion), according to the people, who asked not to be named because the deal is private. UniCredit SpA, which recently increased its stake in the Athens-based bank to around 20%, is advising on the transaction, the people said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the addition of clinical sites in Romania. The Company's application to expand Flamingo-01 into Romania has been formally approved by European regulators, thus adding Romanian sites to the approximately 150 approved sites in Spain, France, Germany, Italy, Poland and the US. At present, there are approximately 123 actively enrolling sites globally. According to the latest data collected by the European Cancer Information System (click here), a total of 12,861 new cases of breast cancer were diagnosed in Romania in 2022, which is the most common cancer diagnosed in women, representing approximately 28% of all cancers in women. Breast cancer is the leading cause of death from cancer in women in Romania with 3,877 deaths in 2022. The Company is collaborating with Dr. Nicoleta Antone, who is leading one of the largest academic breast cancer focused centers in Cluj Napoca, Romania, and her colleagues from at least 3 other sites in Romania. The Romanian clinical sites will be listed here with an interactive map. Dr. Antone will be serving as the national principal investigator in Romania for FLAMINGO-01. She is Head of Breast Cancer Centre at the Chiricuta Institute of Oncology in Cluj Napoca, Romania. She has been the Chair of the Romania Breast Cancer Group since 2021 and a member of the Women's Empowerment Cancer Advocacy Network since 2015. CEO Snehal Patel commented, "Romania is the first of several additional countries in Europe that we hope to add to Flamingo-01 as we now focus on mid-sized population countries with large population centers. We have visited the sites in Romania multiple times to assess study feasibility and provide training, and we are impressed with their facilities and commitment to the study. We look forward to working with Dr. Antone and her colleagues and have sufficiently advanced start-up activities this summer to be potentially screening and enrolling our first Romanian patients in the coming months." About FLAMINGO-01 and GLSI-100 FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients will be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types will be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater. For more information on FLAMINGO-01, please visit the Company's website here and here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the "Contacts and Locations" section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: flamingo-01@ About Breast Cancer and HER2/ Positivity One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. About Greenwich LifeSciences, Inc. Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company's website at and follow the Company's Twitter at Forward-Looking Statement Disclaimer Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law. Company ContactSnehal PatelInvestor RelationsOffice: (832) 819-3232Email: info@ Investor & Public Relations Contact for Greenwich LifeSciencesDave GentryRedChip Companies 1-800-RED CHIP (733 2447)Email: dave@ in to access your portfolio
Yahoo
2 minutes ago
- Yahoo
Pole Star Global buys maritime tech company Clearwater Dynamics
UK-based Pole Star Global, which specialises in voyage optimisation and dark vessel detection, has acquired maritime risk intelligence company Clearwater Dynamics. Financial terms of the transaction remain undisclosed. Clearwater Dynamics, also based in the UK, focuses on situational awareness within high-risk maritime environments. Its Coral platform is known for its role in managing marine war insurance risk, aiding insurers and brokers in the assessment and mitigation of risks within international shipping lanes. Pole Star Global will integrate Clearwater Dynamics' real-time vessel risk monitoring as well as marine insurance capabilities into its existing portfolio. The Coral platform's real-time risk assessment tools are set to complement Pole Star Global's maritime intelligence services, according to a press release from Pole Star Global. Furthermore, the acquisition will bolster Pole Star Global's proprietary data platform, DOMAIN, through the inclusion of new data sources derived from Clearwater Dynamics' operational network. Pole Star Global CEO Bob Skea said: 'This acquisition is a natural extension of our vision. 'Clearwater Dynamics brings the same real-time intelligence to vessel operators and marine underwriters and brokers, creating a seamless, data-rich ecosystem that spans the operational, regulatory and insurance layers of maritime risk.' Clearwater Dynamics CEO Will Unwin stated: 'Joining Pole Star Global enables us to scale Coral's capabilities and reach a wider global audience. Together, we will empower clients to make faster, more confident decisions when navigating the high-risk, high-stakes world of maritime logistics and insurance.' "Pole Star Global buys maritime tech company Clearwater Dynamics " was originally created and published by Life Insurance International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
2 minutes ago
- Yahoo
‘Relief' for motorists as average cost of insurance has fallen by £60 annually
The average cost of motor insurance premiums has fallen by £60 over the past year, according to figures from the Association of British Insurers (ABI). For the period April to June 2025, the average premium was £562 – down from £622 in the same quarter of 2024. Average premiums also fell by £19 compared with the first quarter of the year. The ABI said its members paid out £3.1 billion in car insurance claims during the second quarter of the year. It said repairs continue to be a major contributor to elevated claims costs. The increasing sophistication of vehicles, featuring complex electronics, advanced sensors, and integrated systems, has made repairs more intricate and time-consuming, the ABI said. It added that shortages of skilled technicians, slowing repair times, further inflates costs for insurers. The high cost of claims for theft has also played a role in the payouts, the ABI said. The average claim for theft of and from a vehicle increased by £319 compared with the previous quarter, reaching £11,800. Insurers settled 669,000 claims between April and June, 5% more than 639,000 settled in the first three months of the year. Mark Shepherd, head of general insurance policy at the ABI, said: 'It's encouraging to see motor premiums have fallen for a second consecutive quarter, offering some much-needed relief to drivers. 'But with the cost of cover still weighing on household finances, we must not lose momentum in tackling the persistent pressures driving up claims.' The ABI's research is based on nearly 28 million policies sold a year and is based on prices paid for cover rather than insurance quotes.
